ArticleNature biomedical engineering2020
A retrievable implant for the long-term encapsulation and survival of therapeutic xenogeneic cells.
Article in Nature biomedical engineering, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 159 citations in OpenAlex.
- Retrievable "sea-island" microstructured zwitterionic-silicone hydrogel devices: augmented oxygen transport and anti-fibrosis for sustaining islet survival.Bioactive materials · 2027Article
- Once yearly cell-based therapy for sustained and dose-tunable delivery of monoclonal antibodies.Science advances · 2026Article
- Nanomedicine beyond carriers - devices, cells & living therapeutics.Biomedical microdevices · 2026Review
- Article
- Biomimetic zona pellucida-encapsulated islets for sustained glycaemic control in immunocompetent mice.Nature biomedical engineering · 2026Article
- Investigation of PSBMA-PU Ternary Copolymer-Based Semipermeable Membrane for Macro-Encapsulation of Cells.Macromolecular rapid communications · 2026Article
- A modular hydrogel system with independent control of bioadhesion, fibrosis, and stiffness.Science advances · 2026Article
- A Facile and Versatile Technique for Creating Antifibrotic Coatings on Biomedical Implants.bioRxiv : the preprint server for biology · 2026Article
- Engineering the oxygen microenvironment for pancreatic islet transplants.NPJ Regenerative medicine · 2026Review
- RGD-modified alginate enhances viability, metabolic reprogramming, and cytokine secretion profiles in encapsulated mesenchymal stromal cells.Scientific reports · 2026Article
- A synthetic angiotensin II/ACE2-based hormone shunt controlling experimental hypertension.Nature communications · 2026Article
- Dynamic and living devices for overcoming fibrosis of implanted biomaterials.Bioengineering & translational medicine · 2026Review
- Review
- Avenues for optimization of cardiac therapeutics by minimally invasive delivery.Acta biomaterialia · 2026Review
- Review
- Immune-compatible designs of semiconducting polymers for bioelectronics with suppressed foreign-body response.Nature materials · 2026Article
- Modulating immune response for the prevention and treatment of type 1 diabetes.Frontiers in immunology · 2026Review
- Cell macroencapsulation devices in contemporary research: A systematic review.Regenerative therapy · 2025Review
- Adhesive nonfibrotic bioelectronic interfaces on diverse peripheral nerves for long-term functional neuromodulation.Science advances · 2025Article
- Immunocompatible Elastomer With Enhanced Fibrous Capsule-Resistance and Elasticity by Water-Induced Surface Phase Reconfiguration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
16 authors at 5 institutions in 2 countries.
Funding
Abstract
The long-term function of transplanted therapeutic cells typically requires systemic immune suppression. Here, we show that a retrievable implant comprising a silicone reservoir and a porous polymeric membrane protects human cells encapsulated in it after implant transplantation in the intraperitoneal space of immunocompetent mice. Membranes with pores 1 µm in diameter allowed host macrophages to migrate into the device without the loss of transplanted cells, whereas membranes with pore sizes <0.8 µm prevented their infiltration by immune cells. A synthetic polymer coating prevented fibrosis and was necessary for the long-term function of the device. For >130 days, the device supported human cells engineered to secrete erythropoietin in immunocompetent mice, as well as transgenic human cells carrying an inducible gene circuit for the on-demand secretion of erythropoietin. Pancreatic islets from rats encapsulated in the device and implanted in diabetic mice restored normoglycaemia in the mice for over 75 days. The biocompatible device provides a retrievable solution for the transplantation of engineered cells in the absence of immunosuppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.